KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Long-Term Deferred Tax: 2021-2024

Historic Long-Term Deferred Tax for Moderna (MRNA) over the last 4 years, with Sep 2024 value amounting to $81.0 million.

  • Moderna's Long-Term Deferred Tax was N/A to $81.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $81.0 million, marking a year-over-year change of. This contributed to the annual value of $81.0 million for FY2023, which is 91.75% down from last year.
  • Latest data reveals that Moderna reported Long-Term Deferred Tax of $81.0 million as of Q3 2024, which was down 0.00% from $81.0 million recorded in Q2 2024.
  • In the past 5 years, Moderna's Long-Term Deferred Tax ranged from a high of $1.5 billion in Q2 2023 and a low of $50.0 million during Q1 2021.
  • In the last 3 years, Moderna's Long-Term Deferred Tax had a median value of $653.0 million in 2022 and averaged $627.4 million.
  • As far as peak fluctuations go, Moderna's Long-Term Deferred Tax soared by 1,089.39% in 2022, and later tumbled by 94.53% in 2024.
  • Over the past 4 years, Moderna's Long-Term Deferred Tax (Quarterly) stood at $326.0 million in 2021, then spiked by 201.23% to $982.0 million in 2022, then plummeted by 91.75% to $81.0 million in 2023, then slumped by 94.53% to $81.0 million in 2024.
  • Its Long-Term Deferred Tax stands at $81.0 million for Q3 2024, versus $81.0 million for Q2 2024 and $81.0 million for Q1 2024.